JP4993645B2 - 抗体薬剤結合体および方法 - Google Patents

抗体薬剤結合体および方法 Download PDF

Info

Publication number
JP4993645B2
JP4993645B2 JP2007544495A JP2007544495A JP4993645B2 JP 4993645 B2 JP4993645 B2 JP 4993645B2 JP 2007544495 A JP2007544495 A JP 2007544495A JP 2007544495 A JP2007544495 A JP 2007544495A JP 4993645 B2 JP4993645 B2 JP 4993645B2
Authority
JP
Japan
Prior art keywords
antibody
accession number
genbank accession
international publication
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007544495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521920A (ja
JP2008521920A5 (enExample
Inventor
ルイス ジェイ． ガザード，
エドワード ヒュンスク ハ，
デイビッド ワイ． ジャクソン，
ジョアン ウム，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2008521920A publication Critical patent/JP2008521920A/ja
Publication of JP2008521920A5 publication Critical patent/JP2008521920A5/ja
Application granted granted Critical
Publication of JP4993645B2 publication Critical patent/JP4993645B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007544495A 2004-12-01 2005-11-29 抗体薬剤結合体および方法 Expired - Fee Related JP4993645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63261304P 2004-12-01 2004-12-01
US60/632,613 2004-12-01
PCT/US2005/043409 WO2006060533A2 (en) 2004-12-01 2005-11-29 Conjugates of 1, 8-bis-naphthalimides with an antibody

Publications (3)

Publication Number Publication Date
JP2008521920A JP2008521920A (ja) 2008-06-26
JP2008521920A5 JP2008521920A5 (enExample) 2008-12-25
JP4993645B2 true JP4993645B2 (ja) 2012-08-08

Family

ID=36263731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544495A Expired - Fee Related JP4993645B2 (ja) 2004-12-01 2005-11-29 抗体薬剤結合体および方法

Country Status (3)

Country Link
EP (1) EP1817059A2 (enExample)
JP (1) JP4993645B2 (enExample)
WO (1) WO2006060533A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US8070830B2 (en) 2006-03-24 2011-12-06 L'oreal S.A. Fluorescent entity, dyeing composition containing at least one fluorescent entity comprising at least one heterocycle, with at least one internal cationic charge, and method for lightening keratin materials using said at least one fluorescent entity
FR2898902B1 (fr) * 2006-03-24 2010-09-10 Oreal Colorants particuliers de type naphtalimide, composition tinctoriale comprenant au moins un tel colorant, procede de mise en oeuvre et utilisations
FR2898903B1 (fr) 2006-03-24 2012-08-31 Oreal Composition de teinture comprenant un colorant disulfure fluorescent, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
US7780743B2 (en) 2006-03-24 2010-08-24 L'oreal S.A. Fluorescent entity, dyeing composition containing at least one fluorescent entity, and method for lightening keratin materials using said at least one fluorescent entity
WO2008033891A2 (en) * 2006-09-12 2008-03-20 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Azonafide derived tumor and cancer targeting compounds
SI2474557T1 (sl) 2007-07-16 2014-12-31 Genentech, Inc. Protiteles proti CD79b in imunokonjugati in postopki za uporabo
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
FR2921381B1 (fr) 2007-09-21 2009-10-30 Oreal Colorant hemicyanine styryle thiol/disulfure, composition tinctoriale comprenant ce colorant, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
FR2921373B1 (fr) 2007-09-21 2009-10-30 Oreal Colorant derive d'indole styryle a linker alkylene, composition tinctoriale comprenant ce colorant, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
FR2921376B1 (fr) 2007-09-21 2009-10-30 Oreal Compose styryl tetrahydroquinolinium thiol/disulfure, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
FR2921377B1 (fr) 2007-09-21 2009-10-30 Oreal Compose styryl a motif hydroxy(cyclo)alkylamino thiol/disulfure, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
US8119656B2 (en) 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds
RS54883B1 (sr) 2008-01-31 2016-10-31 Genentech Inc Anti-cd79b antitela i imunokonjugati i metode upotrebe
WO2009144205A1 (en) 2008-05-30 2009-12-03 Basf Se Rylene-based semiconductor materials and methods of preparation and use thereof
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
MX2014012889A (es) 2012-05-01 2014-11-14 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17.
CN104411739B (zh) * 2012-05-02 2017-03-08 路博润高级材料公司 芳族分散剂组合物
JP6280103B2 (ja) 2012-05-15 2018-02-14 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 薬物コンジュゲート、コンジュゲーション方法およびその使用
JP6192022B2 (ja) 2012-05-21 2017-09-06 ジェネンテック， インコーポレイテッド 抗Ｌｙ６Ｅ抗体及びイムノコンジュゲート並びに使用方法
US9463251B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
EP2879708A4 (en) 2012-08-02 2016-03-16 Genentech Inc ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
CN103013497A (zh) * 2012-12-21 2013-04-03 武汉大学 一种巯基荧光探针及其制备方法
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
KR20160055252A (ko) 2013-09-17 2016-05-17 제넨테크, 인크. 항-lgr5 항체의 사용 방법
US9290578B2 (en) 2013-10-21 2016-03-22 Genentech, Inc. Anti-Ly6E antibodies and methods of use
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
CN107043406B (zh) 2015-11-03 2021-08-17 财团法人工业技术研究院 化合物、连接子-药物、及配体-药物耦合体
TR201618160A2 (tr) * 2016-12-09 2018-06-21 T C Istanbul Medipol Ueniversitesi Parazi̇ti̇k ve neoplasti̇k hastaliklarin tedavi̇si̇nde kullanima uygun özgün i̇laç molekülleri̇ ve bunlarin hazirlanmasinda kullanilacak usuller
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN107625771B (zh) * 2017-09-27 2018-12-14 徐州玖胜医疗器械有限公司 一种miR-17基因抑制剂及用于治疗胃癌的用途
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
TW202122116A (zh) 2019-09-05 2021-06-16 西班牙商瑪製藥股份有限公司 藥物抗體偶聯物
CA3175426A1 (en) 2020-04-21 2021-10-28 Alfonso Latorre Lozano Drug antibody conjugates
CN116063284A (zh) * 2023-02-10 2023-05-05 河南大学 一类含有与黏蛋白共价结合片段的肠限制性tgr5激动剂及其在治疗糖尿病药物中的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
DE3707651A1 (de) 1987-03-10 1988-09-22 Knoll Ag Bis-naphthalimide, ihre herstellung und verwendung
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5416089A (en) 1993-06-24 1995-05-16 The Du Pont Merck Pharmaceutical Company Polycyclic and heterocyclic chromophores for bis-imide tumoricidals
IL110460A (en) * 1993-08-18 2001-01-11 Basf Ag Bis-naphthalimides, their preparation and pharmaceutical compositions containing them
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5561042A (en) * 1994-07-22 1996-10-01 Cancer Therapy And Research Center Diamine platinum naphthalimide complexes as antitumor agents
US5641782A (en) * 1995-02-16 1997-06-24 The Dupont Merck Pharmaceutical Company 3-aromatic and 3-heteroaromatic substituted bisnaphthalimides
DK2275119T3 (da) 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
JP3646191B2 (ja) 1996-03-19 2005-05-11 大塚製薬株式会社 ヒト遺伝子
WO2001040309A2 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
ES2568625T3 (es) 1999-11-29 2016-05-03 The Trustees Of Columbia University In The City Of New York Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1311662A2 (en) 2000-08-24 2003-05-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2420140A1 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002215345A1 (en) 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2002054940A2 (en) 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
WO2002098358A2 (en) 2001-06-04 2002-12-12 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
DE60237917D1 (de) 2001-06-05 2010-11-18 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002347428A1 (en) 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002362454A1 (en) 2001-10-03 2003-04-14 Origene Technologies, Inc. Regulated breast cancer genes
AU2002365258A1 (en) * 2001-10-12 2003-09-02 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003055443A2 (en) 2001-10-31 2003-07-10 Alcon, Inc. Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030134790A1 (en) 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
WO2003089624A2 (en) 2002-03-25 2003-10-30 Uab Research Foundation Fc receptor homolog, reagents, and uses thereof
US20040022727A1 (en) 2002-06-18 2004-02-05 Martin Stanton Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
KR20050048615A (ko) 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
JP2004113151A (ja) 2002-09-27 2004-04-15 Sankyo Co Ltd 癌遺伝子及びその用途
US7276372B2 (en) 2002-12-20 2007-10-02 Pdl Biopharma, Inc. Antibodies against GPR64 and uses thereof
US20050227301A1 (en) 2003-01-10 2005-10-13 Polgen Cell cycle progression proteins
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1594893A2 (en) 2003-02-14 2005-11-16 Sagres Discovery, Inc. Therapeutic targets in cancer
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
ES2456325T3 (es) 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos

Also Published As

Publication number Publication date
JP2008521920A (ja) 2008-06-26
WO2006060533A2 (en) 2006-06-08
WO2006060533A3 (en) 2007-07-26
EP1817059A2 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
JP4993645B2 (ja) 抗体薬剤結合体および方法
JP5158804B2 (ja) 複素環置換ビス−１，８−ナフタルイミド化合物、抗体薬物コンジュゲート、および使用方法
US7947839B2 (en) Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
JP5020636B2 (ja) リガンドに結合体化可能なモノメチルバリン化合物
KR101270829B1 (ko) 시스테인 유전자조작 항체 및 접합체
KR101510413B1 (ko) １６１ｐ２ｆ１０ｂ 단백질에 결합하는 항체 약물 컨쥬게이트
EP3381469B1 (en) Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and application thereof
EP3283521A1 (en) Drug conjugates comprising antibodies against claudin 18.2
RU2448117C2 (ru) Монометилвалиновые соединения, способные образовывать конъюгаты с лигандами
HK1254298B (en) Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120302

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120502

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120504

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150518

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4993645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees